Quarterly ResultAug 10, 2026, 04:21 PM
Palisade Bio Advances PALI-2108 to Phase 2; Q2 Net Loss $10.6M
AI Summary
Palisade Bio, Inc. reported its second quarter 2026 financial results and provided a business update, highlighting the advancement of PALI-2108 into Phase 2 development for ulcerative colitis (UC) and Crohn’s disease (CD). The company expects to enroll the first patient for the Phase 2 ASCENTRA-UC trial in 2H 2026 and submit an IND for the Phase 2 ASCENTRA-CD trial in 2H 2026. For Q2 2026, Palisade Bio reported a net loss of $10.6 million, with increased R&D and G&A expenses, but maintains a strong cash position of $125.2 million, sufficient to fund operations through key Phase 2 clinical readouts expected in 2027 and 2028.
Key Highlights
- PALI-2108 Phase 2 ASCENTRA-UC trial enrollment expected in 2H 2026.
- PALI-2108 Phase 2 ASCENTRA-UC primary efficacy results expected in 2H 2027.
- IND for PALI-2108 Phase 2 ASCENTRA-CD trial expected in 2H 2026.
- Net loss for Q2 2026 was $10.6 million, or $0.05 per share.
- Research and development expenses increased to $7.4 million in Q2 2026 from $1.7 million in Q2 2025.
- General and administrative expenses increased to $4.8 million in Q2 2026 from $1.2 million in Q2 2025.
- Cash and cash equivalents totaled $125.2 million as of June 30, 2026.
- Existing cash resources are sufficient to fund operations through primary efficacy readouts in 2H 2027 and early 2028.
Price Impact
More from PALI